Gilder Gagnon Howe & Co’s Royalty Pharma RPRX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-200	Closed	-$8K	–	342
2021 Q4	$8K	Sell	200 -99,451	-100%	-$3.86M	﹤0.01%	378
2021 Q3	$3.6M	Sell	99,651 -89	-0.1%	-$3.46K	0.02%	276
2021 Q2	$4.09M	Sell	99,740 -195	-0.2%	-$8.29K	0.02%	275
2021 Q1	$4.36M	Sell	99,935 -1,206	-1%	-$57.2K	0.02%	250
2020 Q4	$5.06M	Buy	101,141 +41,126	+69%	+$1.74M	0.03%	212
2020 Q3	$2.52M	Buy	60,015 +29,946	+100%	+$1.28M	0.02%	229
2020 Q2	$1.46M	Buy	+30,069	New	+$1.49M	0.01%	228

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gilder Gagnon Howe & Co's RPRX Position: Q1 2022 in Review

Gilder Gagnon Howe & Co sold out of Royalty Pharma (RPRX) in Q1 2022, closing a stake of 200 shares — an estimated $8K sold.

Gilder Gagnon Howe & Co first reported a position in RPRX in Q2 2020 and held it in 7 quarters. The position peaked at $5.06M in Q4 2020. 279 funds tracked by Wall St. Rank hold RPRX as of Q1 2022.

Gilder Gagnon Howe & Co reported no remaining Royalty Pharma position as of Q1 2022 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 200 Royalty Pharma shares in Q1 2022, an estimated $8K.
Gilder Gagnon Howe & Co first reported a position in Royalty Pharma in Q2 2020 and held it in 7 quarters.
Gilder Gagnon Howe & Co's Royalty Pharma position peaked at $5.06M in Q4 2020.
279 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2022.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2022, filed 16 May 2022.